| OBERT, Laurent |
NCT05284357: Post Market Clinical Follow-up Study for Arthroplasty Shoulder System of FX Solutions at the Long Term |
|
|
| Recruiting | N/A | 416 | Europe, RoW | Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System, Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System, Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System, Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System, Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention), Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only), Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System, Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System | FX Solutions | Shoulder Disease, Shoulder Fractures, Shoulder Arthroplasty for Revision of Previous Treatment | 10/22 | 10/22 | | |
| LAROSA, Fabrice |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
NCT02938858: French Registry of First-line Treatment of Acute Promyelocytic Leukemia |
|
|
| Recruiting | N/A | 400 | Europe | | Groupe Francophone des Myelodysplasies, Teva Pharmaceuticals USA | Acute Promyelocytic Leukemia | 10/20 | 10/22 | | |
| Vuitton, Lucine |
TARGET, NCT02425865: Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In- |
|
|
| Completed | 4 | 202 | Europe | GOLIMUMAB | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | ULCERATIVE COLITIS | 10/21 | 01/23 | | |
| Active, not recruiting | 4 | 33 | Europe | Ustekinumab, Stelara, Placebo | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP | Crohn's Disease | 06/25 | 12/25 | | |
| Active, not recruiting | 4 | 150 | Europe | Infliximab, Infliximab injection, Vedolizumab Injection, Vedolizumab | Rennes University Hospital | Ulcerative Colitis | 12/24 | 05/25 | | |
| Active, not recruiting | 4 | 672 | Europe, Canada, US, RoW | Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C | Alimentiv Inc., Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 03/26 | 03/26 | | |
COMET, NCT05040464: Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial |
|
|
| Recruiting | 3 | 166 | Europe | AZA capsules, MTX, blood sample | Centre Hospitalier Universitaire, Amiens | Crohn Disease, Azathioprine, Methotrexate | 08/23 | 03/24 | | |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
Super-Bio, NCT02839278: Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases |
|
|
| Completed | N/A | 150 | Europe | Blood sample | Centre Hospitalier Universitaire de Besancon | Inflammation | 09/24 | 09/24 | | |
SPACIFIX, NCT03841942: Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission |
|
|
| Terminated | N/A | 64 | Europe | clinically-based spacing strategy, Trough level-based strategy | University Hospital, Montpellier | Inflammatory Bowel Diseases | 10/23 | 10/23 | | |
| Recruiting | N/A | 3000 | Europe | | Centre Hospitalier Universitaire de Besancon | Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid, Spondyloarthritis, Psoriatic Arthritis, Psoriasis, Verneuil's Disease | 12/29 | 12/29 | | |
| Toussirot, Eric |
COVIC-19, NCT05271929: Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 |
|
|
| Terminated | 3 | 120 | Europe | Current standard of care and COVID-19 convalescent and vaccinated plasma, Current standard of care | Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen, NHS Blood and Transplant, Erasmus Medical Center | COVID-19 | 01/24 | 06/24 | | |
APO-RA, NCT02903212: Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis |
|
|
| Not yet recruiting | 1/2 | 22 | NA | Autologous apoptotic cells injection | Centre Hospitalier Universitaire de Besancon | Arthritis, Rheumatoid | 06/24 | 12/24 | | |
| Recruiting | N/A | 250 | Europe | measurement of salt intake | Centre Hospitalier Universitaire de Besancon, French Society of Rheumatology | Spondyloarthritis, Axial, Arthritis, Psoriatic | 11/26 | 05/27 | | |
EMOTION, NCT04817072: Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease |
|
|
| Recruiting | N/A | 108 | Europe | Blood sample | Centre Hospitalier Universitaire de Besancon | Rheumatic Diseases, Mood Disorders | 05/24 | 09/24 | | |
| ROBERT, Elise |
| Recruiting | 1/2 | 54 | Europe | Carboplatin, Paclitaxel | Centre Hospitalier Universitaire de Besancon | Oesophagus Cancer, Elderly Patients | 11/28 | 05/29 | | |
| Recruiting | N/A | 30 | Europe | Blood sample | Centre Hospitalier Universitaire de Besancon | Acute Coronary Syndrome | 04/22 | 04/22 | | |
| Recruiting | N/A | 112 | Europe | additional blood sample | Centre Hospitalier Universitaire de Besancon | Breast Cancer | 05/22 | 05/22 | | |
| Perruche, Sylvain |
Super-Bio, NCT02839278: Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases |
|
|
| Completed | N/A | 150 | Europe | Blood sample | Centre Hospitalier Universitaire de Besancon | Inflammation | 09/24 | 09/24 | | |
| Vauchy, Charline |
| Recruiting | 3 | 783 | Europe | Dialysis frequency reduction, Frailty diagnosis | Centre Hospitalier Universitaire de Besancon | Renal Dialysis, Kidney Failure, Chronic, Frailty | 12/22 | 12/22 | | |
| Recruiting | N/A | 20 | Europe | Samples collection | Centre Hospitalier Universitaire de Besancon | Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection | 07/25 | 07/25 | | |
SCOPING, NCT05660174: Identification of Preoperative Parameters to Predict Acute Kidney Injury Risk Following Vascular or Digestive Surgery |
|
|
| Completed | N/A | 2626 | Europe | | Centre Hospitalier Universitaire de Besancon | Acute Kidney Injury | 03/24 | 03/24 | | |
EMOTION, NCT04817072: Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease |
|
|
| Recruiting | N/A | 108 | Europe | Blood sample | Centre Hospitalier Universitaire de Besancon | Rheumatic Diseases, Mood Disorders | 05/24 | 09/24 | | |
| Not yet recruiting | N/A | 343 | Europe | Self-assessment of bleeding events | Centre Hospitalier Universitaire de Besancon | Thrombocytopaenia, Haematological Malignancies | 03/28 | 03/28 | | |
| Recruiting | N/A | 3000 | Europe | | Centre Hospitalier Universitaire de Besancon | Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid, Spondyloarthritis, Psoriatic Arthritis, Psoriasis, Verneuil's Disease | 12/29 | 12/29 | | |
